GE HealthCare Technologies Inc.

GEHC Healthcare Medical Devices

GE HealthCare Technologies Inc.’s revenue for fiscal 2025 (year ended December 2025) was $20.6 billion, up 4.84% from fiscal 2024. In the quarter to June 2026, revenue grew 5.75%, EPS grew 17.0%, free cash flow grew 750.0% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; dividend growth for three consecutive years, revenue growth for five; insiders bought in the last twelve months.

69.57 0.78 −1.11%
Market cap
$31.8B
P/E
16.0×
Fwd P/E
14.4×
Dividend yield
0.26%
F-score
4/9
Altman Z
1.96
Beneish M
−2.33
Dividend safety
74/100

GE HealthCare Technologies Inc. (GEHC) EBITDA

Alert me on EBITDA

GE HealthCare Technologies Inc.'s EBITDA for fiscal 2025 was $3.3B, unchanged from fiscal 2024. Over the twelve months to 30 June 2026 it was $3.3B. Over the past ten years it has ranged from $2.8B (fiscal 2019) to $3.4B (fiscal 2021); the current reading is higher than 71% of that period. GE HealthCare Technologies Inc. ranks 6th of 147 Medical Devices companies by EBITDA.

EBITDA, annual

Embed this chart

Annual newest first

Period EBITDA Change
FY2025 $3.3B 4.21%
FY2024 $3.2B 5.25%
FY2023 $3.0B (3.49%)
FY2022 $3.2B (7.75%)
FY2021 $3.4B 2.09%
FY2020 $3.4B 20.37%
FY2019 $2.8B —

Quarterly newest first

Period EBITDA Change
Jun 2026 $899.0M 34.58%
Mar 2026 $668.0M (31.49%)
Dec 2025 $975.0M 21.88%
Sep 2025 $800.0M (0.12%)
14 more quarters

Against its own ten years

Low $2.8B High $3.4B
Ten-year median $3.2B
Current reading's percentile 71

EBITDA against peers

What EBITDA is

EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.

Reported line item

The full definition of EBITDA →

More on GEHC